SubjectWell has announced its acquisition of Trials24, a provider of global digital patient recruitment solutions. This marks SubjectWell’s first acquisition announcement since it was acquired by New York-based private equity firm WindRose Health Investors in April 2024.
Trials24 is a patient recruitment provider that assists biopharmaceutical companies and contract research organizations in completing clinical trials on time. It offers cutting-edge technology, digital marketing expertise, and an engagement center with local native-language representatives in more than 13 European countries.
SubjectWell is a patient access marketplace that connects patients with chronic health conditions to trials and treatments. Since 2012, SubjectWell has registered tens of millions of patients.
The acquisition will enhance SubjectWell’s ability to connect patients to transformative healthcare across all geographies. SubjectWell and Trials24 have already begun integrating their businesses. The transition will not impact any customer or patient engagements. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 22nd clinical trial deal of 2024. There were 42 clinical trial transactions announced during 2023, and 30 announced during 2022.
